Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 1997

View Archived Issues

Sepracor's levalbuterol NDA accepted by FDA

ICOS and Abbott expand collaboration

Vertex and Alpha Therapeutic end hemoglobin collaboration

Anika completes phase III trial on Orthovisc

Activated Cell Therapy now named Dendreon Corporation

SmithKline Beecham and Incyte form diaDexus

Improved IOP-lowering prostaglandin analogues from Alcon

DuPont Merck discloses new anticoagulants

Large, long-term trial evaluates association between heart rate and mortality

Role of vitamin C in cardiovascular diseases investigated

Lipoprotein(a): new insights into the process of atherosclerosis

Subtype-selective NMDA receptor ligands reported

CV Therapeutics: Q2 1997 highlights

Celltech prepares PDE IV inhibitors

Vitronectin receptor antagonists described by Merck KGaA

Nippon Roche: products under development

DANAMI trial results presented

Texas Biotechnology: Q2 1997 highlights

Merck's asthma treatment receives first approvals

Genzyme General's Seprafilm receives approval in Japan

Neurobiological Technologies files IND for antiedema agent

AccuSite approved in Ireland and The Netherlands

Spotlight on adenosine A1 receptor agonists

DepoTech seeks Canadian approval for DepoCyt

Xoma: Q2 1997 highlights

NeuroSearch compound enters phase I for treatment of dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...